BioSpace News Archive

Resonant Inc. (NASDAQ: RESN), a leader in transforming the way radio frequency, or RF, front-ends are being designed and delivered for mobile handset and wireless devices, today announced that management will present at the LD 500 virtual investor conference, hosted by LD Micro and taking place virtually September 1 – 4, 2020.

Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the underwriters of its previously announced public offering of common stock have fully exercised their option to purchase an additional 500,000 shares at the public offering price of $3.60 per share. After giving effect to the full exercise of the over-allotment option, the to

Daxor Corporation (NYSE MKT: DXR) , an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, filed a Form N-CSR disclosing its schedule of portfolio holdings as of June 30, 2020. Daxor reported an increase in revenue of 29.6% in the Company’s diagnostic division representing strong strides in the commercialization of its BVA-100 Blood Volume Analyzer. Further sales are expected

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced an investigator-initiated study with Cleveland Clinic. The study will assess the effects of DSUVIA on post-o

Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Appli

KromaTiD, Inc. announced today that it was awarded a Direct to Phase II SBIR grant by the National Human Genome Research Institute.

PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (“Primo” or the “Company”) is pleased to announce its intention to proceed with a share consolidation (the “Consolidation”) of its issued and outstanding common shares (“Common Shares”) on the basis of one (1) post-consolidation Common Share for every fifteen (15) pre-consolidation Common Shares.

Medial EarlySign (earlysign.com), a leader in AI-based clinical data solutions to aid in the early detection and prevention of high-burden diseases, announced today that Barts Health, one of the largest National Health Service providers in Britain, has implemented EarlySign’s ColonFlag™ platform to prioritize and care for patients at high risk for developing colon cancer.

Eurofins Discovery is expanding its footprint to serve the growing market of outsourced drug discovery with its high-quality chemistry capabilities

Through fostering partnerships with large organizations in the U.S. healthcare system, newly appointed General Manager Ryan Hovey will spearhead the company’s B2B commercial efforts